Edgewise Therapeutics' Muscular Dystrophy Business acquired by Servier
Servier acquired Edgewise Therapeutics' Muscular Dystrophy Business, a therapeutics brand, on Jul 13, 2026.
Transaction summary
- Target
- Edgewise Therapeutics' Muscular Dystrophy Business
- Acquirer
- Servier
- Seller
- Edgewise Therapeutics
- Announced
- -
- Geography
- -
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-07-27
- Latest update
- 2026-08-03
Value and multiples
100% enterprise value
Undisclosed
Value not disclosed
Basis: FundComb estimate
Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.
EV / revenue
-
Period not stated
Basis: FundComb estimate
EV / EBITDA
-
EBITDA basis not stated
Basis: FundComb estimate
Basis
- Locally publishable after independent verification and publication guards.
Source summary
Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business - PR Newswire
ConfirmedA PR Newswire release states that Servier completed its acquisition of Edgewise Therapeutics' muscular dystrophy business.
Open sourceContinue your research
Related transaction comps
Pharma
Dersimelagon rights acquired by LEO Pharma
2026-08-18 · Confirmed
View transaction → BiotechTubulis acquired by Gilead Sciences
2026-05-21 · Confirmed
View transaction → BiotechAimmune Therapeutics acquired by Sociétés des Produits Nestlé S.A. / Nestlé Health Science
2020-08-31 · Estimated
View transaction → BiotechAtaiBeckley acquired by Eli Lilly and Company
- · Confirmed
View transaction →